Ansun Biopharma Announces Independent Data Monitoring Committee Recommendation Supporting Continued Phase 3 Development of DAS181 in Immunocompromised Patients with Parainfluenza Infection

Committee Recommends Expanding Sample Size After Interim Analysis Places Study in Protocol-Defined Promising Zone SAN DIEGO, June 1, 2026 /PRNewswire/ -- Ansun Biopharma, Inc., a clinical-stage biopharmaceutical company, today announced that its independent Data Monitoring Committee (DMC)...